Immune Repertoire Sequencing Market, by Product Type (Instruments, and Reagents and Kits), by Application (Cancer Immunotherapy, Infectious Disease, Asthma and Allergy, Biomarker Discovery, Organ Transplant, Immune Response, Autoimmune Diseases, and Other

Immune Repertoire Sequencing Market, by Product Type (Instruments, and Reagents and Kits), by Application (Cancer Immunotherapy, Infectious Disease, Asthma and Allergy, Biomarker Discovery, Organ Transplant, Immune Response, Autoimmune Diseases, and Others), by End User (Diagnostic Labs, Biopharmaceutical Companies, Research Institutes, and Others), and by Geography - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022 - 2028

Immune repertoire refers to sub-type protein that an organism’s immune system creates. Immune systems in vertebrates have six key types of proteins- two immunoglobulin and four T cell receptors. Immune repertoire sequencing enables researchers and scientists to examine and understand adaptive immune-mediated diseases. Immune repertoire sequencing is also widely applicable in biomarker discovery, infectious disease research, asthma and allergy research, and cancer immunotherapy.
Market Dynamics
Increasing prevalence of cancer worldwide is expected to boost immune repertoire sequencing market growth. According to National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer were diagnosed in the U.S., with around 595,690 deaths from the disease. Moreover, the number of people suffering from cancer is expected to reach to 19 million by 2024. According to the Cancer Atlas, 2012, about 1.1 million new cancer cases and 600,000 cancer deaths are reported annually in Latin America and the Caribbean, where lung cancer is the leading cause of cancer death for both sexes.
However, factors such as high cost associated with certain sequencing platforms and data analytic services coupled with product recalls are expected to hinder growth of the immune repertoire sequencing market during the forecast period. For instance, in 2015, Illumina Inc. recalled its Illumina MiSeqDx Universal Kit 1.0, due to software limitation when using the product on MiSeqDx instrument. The software could not report insertions or deletions at specific genomic locations with respect to the primer.
Key features of the study:
This report provides in-depth analysis of the immune repertoire sequencing market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global immune repertoire sequencing market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Thermo Fisher Scientific, Inc., Illumina Inc., ArcherDX, Inc., Roche Holding AG, Pacific Biosciences, CD Genomics, Atreca, Inc., Adaptive Biotechnologies, Oxford Nanopore Technologies, Ltd., Qiagen N.V., Agilent Technologies, Inc., and Takara Bio, Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global immune repertoire sequencing market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for immune repertoire sequencing market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:
Global Immune Repertoire Sequencing Market, By Product Type:
Assay Kits
T-Cell Receptor (TCR) Kits
B-Cell Receptor (BCR) Kits
Instruments
Global Immune Repertoire Sequencing Market, By Application:
Cancer Immunotherapy
Biomarker Discovery
Autoimmune Diseases
Vaccine Development and Efficacy
Transplant Rejection and Tolerance
Infectious Diseases
Other Applications
Global Immune Repertoire Sequencing Market, By End User:
Diagnostic Labs
Biotechnology and Pharmaceutical Companies
Academic and Research Institutes
Others
Global Immune Repertoire Sequencing Market, By Region:
North America
By Country:
U.S.
Canada
By Product Type:
Assay Kits
T-Cell Receptor (TCR) Kits
B-Cell Receptor (BCR) Kits
Instruments
By Application:
Cancer Immunotherapy
Biomarker Discovery
Autoimmune Diseases
Vaccine Development and Efficacy
Transplant Rejection and Tolerance
Infectious Diseases
Other Applications
By End User:
Diagnostic Labs
Biotechnology and Pharmaceutical Companies
Academic and Research Institutes
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Product Type:
Assay Kits
T-Cell Receptor (TCR) Kits
B-Cell Receptor (BCR) Kits
Instruments
By Application:
Cancer Immunotherapy
Biomarker Discovery
Autoimmune Diseases
Vaccine Development and Efficacy
Transplant Rejection and Tolerance
Infectious Diseases
Other Applications
By End User:
Diagnostic Labs
Biotechnology and Pharmaceutical Companies
Academic and Research Institutes
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Product Type:
Assay Kits
T-Cell Receptor (TCR) Kits
B-Cell Receptor (BCR) Kits
Instruments
By Application:
Cancer Immunotherapy
Biomarker Discovery
Autoimmune Diseases
Vaccine Development and Efficacy
Transplant Rejection and Tolerance
Infectious Diseases
Other Applications
By End User:
Diagnostic Labs
Biotechnology and Pharmaceutical Companies
Academic and Research Institutes
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Product Type:
Assay Kits
T-Cell Receptor (TCR) Kits
B-Cell Receptor (BCR) Kits
Instruments
By Application:
Cancer Immunotherapy
Biomarker Discovery
Autoimmune Diseases
Vaccine Development and Efficacy
Transplant Rejection and Tolerance
Infectious Diseases
Other Applications
By End User:
Diagnostic Labs
Biotechnology and Pharmaceutical Companies
Academic and Research Institutes
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Product Type:
Assay Kits
T-Cell Receptor (TCR) Kits
B-Cell Receptor (BCR) Kits
Instruments
By Application:
Cancer Immunotherapy
Biomarker Discovery
Autoimmune Diseases
Vaccine Development and Efficacy
Transplant Rejection and Tolerance
Infectious Diseases
Other Applications
By End User:
Diagnostic Labs
Biotechnology and Pharmaceutical Companies
Academic and Research Institutes
Africa
By Country:
South Africa
Central Africa
North Africa
By Product Type:
Assay Kits
T-Cell Receptor (TCR) Kits
B-Cell Receptor (BCR) Kits
Instruments
By Application:
Cancer Immunotherapy
Biomarker Discovery
Autoimmune Diseases
Vaccine Development and Efficacy
Transplant Rejection and Tolerance
Infectious Diseases
Other Applications
By End User:
Diagnostic Labs
Biotechnology and Pharmaceutical Companies
Academic and Research Institutes
Company Profiles
Thermo Fisher Scientific, Inc.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Illumina Inc.
ArcherDX, Inc
Roche Holding AG
Pacific Biosciences
CD Genomics
Atreca, Inc.
Adaptive Biotechnologies
Oxford Nanopore Technologies, Ltd.
Qiagen N.V.
Agilent Technologies, Inc.
Takara Bio, Inc.
“*” marked represents similar segmentation in other categories in the respective section.